Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma

Nearly all patients with BRAF-mutant melanoma will progress on BRAF inhibitor monotherapy and combination BRAF/MEK inhibitor therapy within the first year of therapy. In the vast majority of progressing melanomas, resistance occurs via the re-activation of MAPK signalling, commonly via alterations i...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncogenesis
Asıl Yazarlar: Irvine, Mal, Stewart, Ashleigh, Pedersen, Bernadette, Boyd, Suzanah, Kefford, Richard, Rizos, Helen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6148266/
https://ncbi.nlm.nih.gov/pubmed/30237495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-018-0081-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller